EGFR-tyrosine kinase inhibitors (TKIs) have emerged as an effective therapy among patients with advanced stage EGFR-mutant non-small cell lung cancer (NSCLC), as they result in more favorable outcomes as well as a better quality of life [9–12]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.